Project Grant HT94252510671
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$837K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
This $952,162 federal Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop novel, improved adeno-associated virus (AAV) vectors for the treatment of amyotrophic lateral sclerosis (ALS). The award was granted to the University of Massachusetts Medical School (UMass Medical) in Worcester, MA, with a period of performance from August 1, 2025 to July 31, 2027. UMass Medical, as a prominent academic...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The University of Massachusetts was awarded a $153,309 project grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2024, supports research to extend the period of performance for a project titled "Modeling Spread Through Air Spaces with Lung-on-a-Chip". This research aims to transform healthcare for military service members, veterans, and the broader public through innovative biomedical...
The University of Massachusetts Medical School was awarded a $749,992 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to study the role of SCARF1 in efferocytosis and the prevention of lupus. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The University of California, Los Angeles (UCLA) was awarded a $1,181,251 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on April 15, 2025, supports research to develop neuronal exosome-based biomarkers for amyotrophic lateral sclerosis (ALS) diagnosis and disease progression tracking. The project aims to transform healthcare for military service members, veterans, and the public through innovative...